Novo Nordisk A/S (OMXCOP:NOVO_B) sued Eli Lilly over obesity‑drug ads while repurchasing 24.96M B shares into a 0.9% treasury stake, as Wegovy demand surges with Medicare pilots boosting senior access amid debate over competing GLP‑1 vs Lilly’s multi‑target retatrutide.
Previous Week Recap
- Novo Nordisk Sues Lilly Over Ads: Novo Nordisk (NOVO_B) sued Eli Lilly in New Jersey, alleging false advertising and unfair competition over obesity drug ads; seeks injunctions, corrective ads and damages tied to Lilly’s ad profits.
- Novo Repurchases B Shares: NOVO_B repurchased 24,959,179 B shares Feb 4–Jul 17, 2026 for DKK 6.85bn (avg DKK 274.58). As of Jul 17, 2026 treasury holds 42,144,480 B shares (0.9%).
- Medicare Wegovy Access Demand Rises: Traders: Novo Nordisk (NOVO_B) sees strong demand as Medicare pilots 18-month Wegovy access for seniors; rapid prior authorizations reported, though some beneficiaries face mixed coverage and delays
- Wegovy vs Retatrutide Mechanisms: NOVO_B: Wegovy (obesity drug) is GLP‑1 only, while Eli Lilly’s retatrutide targets GLP‑1, GIP and glucagon—highlighting differing mechanisms relevant to traders tracking competitive landscape.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.